News | January 20, 2026
Syngene locks in Bristol Myers Squibb alliance through 2035
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
The expanded agreement significantly widens the scope of integrated services across the entire drug development lifecycle
India in the Changing Landscape of Life-Sciences Research & Development
The initiative is being led through the Bank’s CSR programme, Parivartan, in partnership with the Indian Cancer Society
Sabitha highlighted the growing relevance of minimally invasive therapies in modern medicine
BFF provides bookable fermentation upscaling capacity, process expertise, and quality procedures for pilot campaigns, generating decision-grade data without companies needing to build their own facilities
This collaboration combines Organon’s commercial agility with Daiichi Sankyo’s expertise in cardiovascular innovation to bring Nilemdo to patients in France, Denmark, Iceland, Sweden, Finland and Norway
ALV-100 is a bifunctional fusion protein combining glucose-dependent insulinotropic polypeptide receptor (GIPR) antagonism with glucagon-like peptide-1 receptor agonism
Phase 3 study met all primary and secondary endpoints, demonstrating superior convenience, strong efficacy, and excellent safety versus conventional ondansetron injections
This product has only one approved generic and one authorized generic with an addressable market share of US$ 172 million
Subscribe To Our Newsletter & Stay Updated
